A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Is this Study for You?

Let's Get Started!




Highlands Ranch Hospital
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Jessica McDermott

Jessica McDermott

Study ID

Protocol Number: 23-2332

More information available at ClinicalTrials.gov: NCT06129864


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers